Managing Immune Checkpoint-Blocking Antibody Side Effects
Immune checkpoint-blocking antibodies that enhance the immune system's ability to fight cancer are becoming important components of treatment for patients with a variety of malignancies. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) was the first immune checkpoint to be clinically target...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Revisão |
| Idioma: | inglés |
| Publicado: |
2015
|
| Acceso en liña: | https://doi.org/10.14694/edbook_am.2015.35.76 https://ascopubs.org/doi/pdfdirect/10.14694/EdBook_AM.2015.35.76 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Sexa o primeiro en deixar un comentario!